In last trading session, Relmada Therapeutics Inc (NASDAQ:RLMD) saw 32.59 million shares changing hands with its beta currently measuring -0.02. Company’s recent per share price level of $0.69 trading at $0.31 or 82.54% at ring of the bell on the day assigns it a market valuation of $22.91M. That closing price of RLMD’s stock is at a discount of -547.83% from its 52-week high price of $4.47 and is indicating a premium of 65.22% from its 52-week low price of $0.24. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 1.84 million shares which gives us an average trading volume of 1.16 million if we extend that period to 3-months.
For Relmada Therapeutics Inc (RLMD), analysts’ consensus is at an average recommendation of Sell while assigning it a mean rating of 3.00. Splitting up the data highlights that, out of 1 analysts covering the stock, 1 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 0 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of 0 in the current quarter.
Relmada Therapeutics Inc (NASDAQ:RLMD) trade information
Upright in the green during last session for gaining 82.54%, in the last five days RLMD remained trading in the green while hitting it’s week-highest on Wednesday, 04/23/25 when the stock touched $0.69 price level, adding 1.43% to its value on the day. Relmada Therapeutics Inc’s shares saw a change of 32.69% in year-to-date performance and have moved 124.03% in past 5-day. Relmada Therapeutics Inc (NASDAQ:RLMD) showed a performance of 128.48% in past 30-days. Number of shares sold short was 1.62 million shares which calculate 4.07 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 7 to the stock, which implies a rise of 90.14% to its current value. Analysts have been projecting 2 as a low price target for the stock while placing it at a high target of 8. It follows that stock’s current price would drop -189.86% in reaching the projected high whereas dropping to the targeted low would mean a loss of -189.86% for stock’s current value.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 0.68% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 34.72% while estimates for its earnings growth in next 5 years are of 19.94%.
Relmada Therapeutics Inc (NASDAQ:RLMD)’s Major holders
Insiders are in possession of 7.28% of company’s total shares while institution are holding 27.08 percent of that, with stock having share float percentage of 29.20%. Investors also watch the number of corporate investors in a company very closely, which is 27.08% institutions for Relmada Therapeutics Inc that are currently holding shares of the company. VANGUARD GROUP INC is the top institutional holder at RLMD for having 1.26 million shares of worth $3.77 million. And as of 2024-06-30, it was holding 16.6593 of the company’s outstanding shares.
The second largest institutional holder is DEEP TRACK CAPITAL, LP, which was holding about 1.23 million shares on 2024-06-30. The number of shares represents firm’s hold over 16.3686 of outstanding shares, having a total worth of $3.7 million.
On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and Franklin Strategic Series-FRANKLIN BIOTECHNOLOGY DISCOVERY FUND are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024 , the former fund manager was holding 851.92 shares of worth $0.59 million or 8.61% of the total outstanding shares. The later fund manager was in possession of 456.4 shares on Jan 31, 2025 , making its stake of worth around $0.31 million in the company or a holder of 4.61% of company’s stock.
